A phase i trial of oxaliplatin in combination with docetaxel in patients with advanced solid tumors

Syma Iqbal, Heinz Josef Lenz, David R Gandara, Stephen I. Shibata, Susan Groshen, Timothy W. Synold, Edward M. Newman

Research output: Contribution to journalArticle

3 Scopus citations


The primary objective of this trial was to establish the maximum tolerated dose (MTD) of oxaliplatin 130 mg/m2 preceded by escalating doses of docetaxel 60 mg/m2 (75, 90, 100 mg/m2) administered every 3 weeks. A total of 11 patients were entered; 10 evaluable for response: 4 stable disease (liver, ovary and esophagus) and 1 partial remission (esophagus). At dose level 1, there was 1 dose-limiting toxicity (DLT) (grade 3 allergic reaction). At dose level 2, there were 3 DLTs (3 grade 4 neutropenia, grade 3 gastritis, diarrhea, hypophosphatemia, neuro-mood). The MTD is docetaxel 60 mg/m2 with oxaliplatin 130 mg/m2.

Original languageEnglish (US)
Pages (from-to)85-91
Number of pages7
JournalCancer Chemotherapy and Pharmacology
Issue number1
StatePublished - Jul 2013



  • Docetaxel
  • Oxaliplatin
  • Oxaliplatin and Docetaxel
  • Phase I

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Toxicology

Cite this